Becton, Dickinson and Company (BDX) Stock Score, Valuation & Financial Research
Becton, Dickinson and Company is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for BDX
Becton, Dickinson and Company currently has a Wall Street Score of 26/100. The stored market price is $177.85. Its financial score is 24/100. Its valuation score is 0/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Becton, Dickinson and Company does
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injectio
BDX financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $177.85
- Market capitalization:
- $49.00B
- Revenue:
- $20.84B
- Net income:
- $941.0M
- Free cash flow:
- $2.67B
- Cash:
- $708.0M
- Total debt:
- $16.81B
- EPS:
- 3.32
- P/E ratio:
- 53.6x
- Financial score:
- 24/100
- Valuation score:
- 0/100
- Revenue score:
- 13/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $2.67B, showing positive cash generation.
- The balance sheet shows $708.0M of cash versus $16.81B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.2 points: BDX increased 0.2 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BDX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.